Nicola Baldini

Prof. Nicola Baldini

1. Laboratory for Orthopaedic Pathophysiology and Regenerative Medicine, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy
+1

Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2020 in Science
Verified
Journal Article
Closed access
PDF file
DNDeborah Nejman
Deborah Nejman
ILIlana Livyatan
Ilana Livyatan
GFGarold Fuks
Garold Fuks
NGNancy Gavert
Nancy Gavert
YZYaara Zwang
Yaara Zwang
RSRavid Straussman
Ravid Straussman
Profiling tumor bacteria: Bacteria are well-known residents in human tumors, but whether their presence is advantageous to the tumors or to the bacteria themselves has been unclear. As an initial step toward addressing this question, Nejman et al. produced an exhaustive catalog of the bacteria present in more than 1500 human tumors representing seven different tumor types (see the Perspective by Atreya and Turnbaugh). They found that the bacteria within tumors were localized within both cancer cells and immune cells and that the bacterial composition varied according to tumor type. Certain biologically plausible associations were identified. For example, breast cancer subtypes characterized by increased oxidative stress were enriched in bacteria that produce mycothiol, which can detoxify reactive oxygen species. Science , this issue p. 973 ; see also p. 938

1 July 2015 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
SBSerena Rubina Baglio
Serena Rubina Baglio
KRKoos Rooijers
Koos Rooijers
Danijela Koppers-LalicDanijela Koppers-Lalic
Danijela Koppers-Lalic
FVFrederik J. Verweij
Frederik J. Verweij
MPMaria Perezlanzon
Maria Perezlanzon
DPD. Michiel Pegtel
D. Michiel Pegtel
Introduction: Administration of mesenchymal stem cells (MSCs) represents a promising treatment option for patients suffering from immunological and degenerative disorders. Accumulating evidence indicates that the healing effects of MSCs are mainly related to unique paracrine properties, opening opportunities for secretome-based therapies. Apart from soluble factors, MSCs release functional small RNAs via extracellular vesicles (EVs) that seem to convey essential features of MSCs. Here we set out to characterize the full small RNAome of MSC-produced exosomes. Methods: We set up a protocol for isolating exosomes released by early passage adipose- (ASC) and bone marrow-MSCs (BMSC) and characterized them via electron microscopy, protein analysis and small RNA-sequencing. We developed a bioinformatics pipeline to define the exosome-enclosed RNA species and performed the first complete small RNA characterization of BMSCs and ASCs and their corresponding exosomes in biological replicates. Results: Our analysis revealed that primary ASCs and BMSCs have highly similar small RNA expression profiles dominated by miRNAs and snoRNAs (together 64-71 %), of which 150–200 miRNAs are present at physiological levels. In contrast, the miRNA pool in MSC exosomes is only 2-5 % of the total small RNAome and is dominated by a minor subset of miRNAs. Nevertheless, the miRNAs in exosomes do not merely reflect the cellular content and a defined set of miRNAs are overrepresented in exosomes compared to the cell of origin. Moreover, multiple highly expressed miRNAs are precluded from exosomal sorting, consistent with the notion that these miRNAs are involved in functional repression of RNA targets. While ASC and BMSC exosomes are similar in RNA class distribution and composition, we observed striking differences in the sorting of evolutionary conserved tRNA species that seems associated with the differentiation status of MSCs, as defined by Sox2, POU5F1A/B and Nanog expression. Conclusions: We demonstrate that primary MSCs release small RNAs via exosomes, which are increasingly implicated in intercellular communications. tRNAs species, and in particular tRNA halves, are preferentially released and their specific sorting into exosomes is related to MSC tissue origin and stemness. These findings may help to understand how MSCs impact neighboring or distant cells with possible consequences for their therapeutic usage.

1 January 2012 in Frontiers in Physiology
Verified
Journal Article
Open access
SBSerena Rubina Baglio
Serena Rubina Baglio
DPD. Michiel Pegtel
D. Michiel Pegtel
Nicola BaldiniNicola Baldini
Nicola Baldini
Mesenchymal stem cells (MSCs) are adult multipotent cells that give rise to various cell types of the mesodermal germ layer. MSCs are of great interest in the field of regenerative medicine and cancer therapy because of their unique ability to home to damaged and cancerous tissue. These cells also regulate the immune response and contribute to reparative processes in different pathological conditions, including musculoskeletal and cardiovascular diseases. The use of MSCs for tissue repair was initially based on the hypothesis that these cells home to and differentiate within the injured tissue into specialized cells. However, it now appears that only a small proportion of transplanted MSCs actually integrate and survive in host tissues. Thus, the predominant mechanism by which MSCs participate in tissue repair seems to be related to their paracrine activity. Indeed, MSCs provide the microenvironment with a multitude of trophic and survival signals including growth factors and cytokines. Recent discoveries suggest that lipid microvesicles released by MSCs may also be important in the physiological function of these cells. Over the past few years the biological relevance of micro- and nano-vesicles released by cells in intercellular communication has been established. Alongside the conventional mediators of cell secretome, these sophisticated nanovesicles transfer proteins, lipids and, most importantly, various forms of RNAs to neighboring cells, thereby mediating a variety of biological responses. The physiological role of MSC-derived vesicles (MSC-MVs) is currently not well understood. Nevertheless, encouraging results indicate that MSC-MVs have similar protective and reparative properties as their cellular counterparts in tissue repair and possibly anti-cancer therapy. Thus, MSC-MVs represent a promising opportunity to develop novel cell-free therapy approaches that might overcome the obstacles and risks associated with the use of native or engineered stem cells.

12 January 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
FPFrancesca Perut
Francesca Perut
LRLaura Roncuzzi
Laura Roncuzzi
Sofia AvnetSofia Avnet
Sofia Avnet
AMAnnamaria Massa
Annamaria Massa
NZNicoletta Zini
Nicoletta Zini
Nicola BaldiniNicola Baldini
Nicola Baldini
Plant-derived exosome-like nanovesicles (EPDENs) have recently been isolated and evaluated as potential bioactive nutraceutical biomolecules. It has been hypothesized that EPDENs may exert their activity on mammalian cells through their specific cargo. In this study, we isolated and purified EPDENs from the strawberry juice of Fragaria x ananassa (cv. Romina), a new cultivar characterized by a high content of anthocyanins, folic acid, flavonols, and vitamin C and an elevated antioxidant capacity. Fragaria-derived EPDENs were purified by a series of centrifugation and filtration steps. EPDENs showed size and morphology similar to mammalian extracellular nanovesicles. The internalization of Fragaria-derived EPDENs by human mesenchymal stromal cells (MSCs) did not negatively affect their viability, and the pretreatment of MSCs with Fragaria-derived EPDENs prevented oxidative stress in a dose-dependent manner. This is possibly due to the presence of vitamin C inside the nanovesicle membrane. The analysis of EPDEN cargo also revealed the presence of small RNAs and miRNAs. These findings suggest that Fragaria-derived EPDENs may be considered nanoshuttles contained in food, with potential health-promoting activity.

3 December 2010 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
KAK. Arvidson
K. Arvidson
BABasem Abdallah
Basem Abdallah
LAL. A. Applegate
L. A. Applegate
Nicola BaldiniNicola Baldini
Nicola Baldini
ECE. Cenni
E. Cenni
AFA. Finne-Wistrand
A. Finne-Wistrand
• Introduction • Bone fracture healing and healing problems • Biomaterial scaffolds and tissue engineering in bone formation ‐ Bone tissue engineering ‐ Biomaterial scaffolds ‐ Synthetic scaffolds ‐ Micro‐ and nanostructural properties of scaffolds ‐ Conclusion • Mesenchymal stem cells and osteogenesis ‐ Bone tissue ‐ Origin of osteoblasts ‐ Isolation and characterization of bone marrow derived MSC ‐ In vitro differentiation of MSC into osteoblast lineage cells ‐ In vivo differentiation of MSC into bone ‐ Factors and pathways controlling osteoblast differentiation of hMSC ‐ Defining the relationship between osteoblast and adipocyte differentiation from MSC ‐ MSC and sex hormones ‐ Effect of aging on osteoblastogenesis ‐ Conclusion • Embryonic, foetal and adult stem cells in osteogenesis ‐ Cell‐based therapies for bone ‐ Specific features of bone cells needed to be advantageous for clinical use ‐ Development of therapeutic biological agents ‐ Clinical application concerns ‐ Conclusion • Platelet‐rich plasma (PRP), growth factors and osteogenesis ‐ PRP effects in vitro on the cells involved in bone repair ‐ PRP effects on osteoblasts ‐ PRP effects on osteoclasts ‐ PRP effects on endothelial cells ‐ PRP effects in vivo on experimental animals ‐ The clinical use of PRP for bone repair ‐ Non‐union ‐ Distraction osteogenesis ‐ Spinal fusion ‐ Foot and ankle surgery ‐ Total knee arthroplasty ‐ Odontostomatology and maxillofacial surgery ‐ Conclusion • Molecular control of osteogenesis ‐ TGF‐β signalling ‐ FGF signalling ‐ IGF signalling ‐ PDGF signalling ‐ MAPK signalling pathway ‐ Wnt signalling pathway ‐ Hedgehog signalling ‐ Notch signalling ‐ Ephrin signalling ‐ Transcription factors regulating osteoblast differentiation ‐ Conclusion • Summary This invited review covers research areas of central importance for orthopaedic and maxillofacial bone tissue repair, including normal fracture healing and healing problems, biomaterial scaffolds for tissue engineering, mesenchymal and foetal stem cells, effects of sex steroids on mesenchymal stem cells, use of platelet‐rich plasma for tissue repair, osteogenesis and its molecular markers. A variety of cells in addition to stem cells, as well as advances in materials science to meet specific requirements for bone and soft tissue regeneration by addition of bioactive molecules, are discussed.

23 November 1995 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
Nicola BaldiniNicola Baldini
Nicola Baldini
Katia ScotlandiKatia Scotlandi
Katia Scotlandi
Giovanni Barbanti BrodanoGiovanni Barbanti Brodano
Giovanni Barbanti Brodano
Maria Cristina ManaraMaria Cristina Manara
Maria Cristina Manara
DMDaniela Maurici
Daniela Maurici
Massimo SerraMassimo Serra
Massimo Serra
Increased levels of P-glycoprotein occur in some osteosarcomas. In this study we determined the relation between P-glycoprotein status and outcome in patients with high-grade osteosarcoma. P-glycoprotein status was determined immunohistochemically in specimens of osteosarcoma of the extremities (stage II) from 92 patients who were treated with surgery and chemotherapy. The P-glycoprotein status was analyzed in relation to the length of event-free survival. The presence of increased levels of P-glycoprotein in the osteosarcoma was significantly associated with a decreased probability of remaining event-free after diagnosis (P = 0.002). In a multivariate analysis, P-glycoprotein status (P = 0.001) and the extent of tumor necrosis after preoperative chemotherapy (P = 0.04) were independent predictors of clinical outcome. The risk of adverse events was increased substantially (rate ratio, 3.37; 95 percent confidence interval, 1.60 to 7.10) among patients with increased levels of P-glycoprotein in tumor cells, as compared with patients who did not have increased levels of P-glycoprotein in tumor cells. In patients with high-grade osteosarcoma treated with surgery and chemotherapy, the presence of increased levels of P-glycoprotein in tumor cells is associated with a significantly increased risk of adverse events and is independent of the extent of necrosis after preoperative chemotherapy.